Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune appoints chief business officer

Fabian Buller will further drive the biopharma’s growth strategy

Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

Buller joins the biopharmaceutical group’s executive team, bringing with him eight years of biotech and pharma experience.

Prior to joining Neurimmune, Buller served as director new ventures at Johnson & Johnson Innovation, as well as director of business development of Covagen.

Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins our company to further drive our growth strategy.

“Dr Buller has an impressive track record in business development and licensing transactions.

“He will play a key role in realising opportunities that will allow us to bring novel therapeutics to patients.”

2nd May 2018

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

    PMHub

    Add my company
    Wordbird

    Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

    Latest intelligence

    RWE Blog 3: Is real-world evidence the holy grail
    We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
    What do Healthcare Professionals think about the inclusion of remote selling techniques?
    Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
    Drug pricing and competition
    Strengthening business competition and reducing anti-competitive practices
    How the CMA is tackling high prices for essential drugs...

    Infographics